TXG · 10x Genomics, Inc.
10x Genomics (TXG) builds tools and consumables for single-cell and spatial genomics. Ongoing adoption of multiomics workflows positions TXG as a plays-and-shovels beneficiary of rising data generation and analysis needs across research, diagnostics, and drug development.
Recent proof-backed calls
Recent internal coverage includes ARK’s Big Ideas 2026: Multiomics, which frames multi-layer molecular measurement as a long-term growth driver for sequencing, single-cell, and proteomics platforms.
ARK’s Big Ideas 2026 (Multiomics) segment outlines the investment case for “multiomics” (integrating genomics, transcriptomics, proteomics, etc.) as biology moves from single-layer measurement to multi-layer data + computation. The talk highlights downstream implications across (1) data generation (sequencing/single-cell/proteomics platforms), (2) diagnostics (earlier, cheaper, more precise testing), (3) drug development (better target ID/stratification), and (4) therapeutics (more precise, pote
Latest market-close explanation
On 2026-04-13 TXG closed at $23.58 (+1.33%) on increased volume. Intraday range: $22.91–$24.30. Internal coverage referenced Big Ideas 2026: Multiomics.
**TXG** (10x Genomics, Inc.) moved **+1.33%** on 2026-04-13, closing at **$23.58** after a previous close of **$23.27**. Intraday range was **$22.91** to **$24.30**. Volume changed **+38.7%** versus the prior session. Recent internal coverage also touched TXG: **Big Ideas 2026: Multiomics**.
Current stance
Current recommendation: buy. The thesis identifies TXG as a beneficiary of multiomics-driven growth in data generation and downstream analytics.
- beneficiary via Multiomics ‘picks-and-shovels’ benefit from rising data generation and analysis demand. from https://www.youtube.com/@ARKInvest2015 (confidence 0.58)
Top authors on this ticker
Active and historical plays
Big Ideas 2026: Multiomics — Direct exposure to single-cell and spatial multiomics workflows as labs expand beyond bulk genomics; benefits for tools-and-consumables providers.
Unlock full ticker monitoring
See the full Big Ideas 2026 coverage and research notes for details on multiomics implications for data generation, diagnostics, drug development, and therapeutics.